Enlivex Ltd (ENLV) is a clinical-stage biotechnology company headquartered in Israel that has drawn outsized attention not only for its Allocetra immunotherapy pipeline but also for an unconventional treasury strategy built around digital assets, including the RAIN token. That dual identity makes each quarterly report more than a routine update: results can swing sharply depending on the mark-to-market value of the company's cryptocurrency-linked holdings. In its fourth-quarter 2025 report, RAIN token appreciation pushed total assets to roughly $2.31 billion and drove a surge in reported net income. With the upcoming third-quarter 2026 release, investors will weigh clinical milestones against the ongoing volatility of a crypto-exposed balance sheet. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Analysts tracked by major financial data providers project a net loss of approximately $0.28 per share for the third quarter of 2026, based on a three-analyst consensus. On a reverse-split-adjusted basis following the 16-for-1 share consolidation completed in late October 2026, that estimate translates to a materially larger per-share loss, underscoring how the reverse split distorts straightforward comparisons. Revenue is expected to be negligible, as the company has no commercialized product generating sales.
Investors will therefore focus less on top-line figures and more on research and development (R&D) spending, general and administrative costs, and the company's cash position. Prior quarters offer a cautionary backdrop: the fourth quarter of 2025 delivered net income of roughly $1.23 billion and diluted earnings per share (EPS, profit divided by outstanding shares) of about $25.48, driven almost entirely by RAIN token appreciation, and the stock rose roughly 15.79% following that report. By contrast, more recent quarters have shown a return to operating losses, reflecting the unpredictable influence of the digital-asset treasury.
Sentiment heading into the third-quarter 2026 report is unusually mixed. On one hand, Enlivex's FDA-cleared Phase IIb osteoarthritis trial for Allocetra gives long-term investors a tangible clinical catalyst to track. On the other, the company's exposure to digital-asset volatility has introduced a level of price unpredictability rarely seen in traditional biotech names. The late-October reverse stock split further muddied the picture, changing share counts and per-share metrics at a time when investors were already parsing unusually large swings in reported earnings. Heading into the release, traders are likely to remain sensitive both to any updates on clinical timelines and to the current value of the company's token holdings, making the market reaction difficult to predict from operating results alone. From what I see, this tension is what makes the stock particularly interesting to follow.
Beyond the immediate earnings print, several factors will shape how investors evaluate Enlivex going forward.
First, the Allocetra clinical program remains the core fundamental story. With the FDA (U.S. Food and Drug Administration) having cleared a Phase IIb osteoarthritis trial and top-line data expected in 2027, any commentary on enrollment progress, timelines, or additional indications will be closely watched.
Second, the digital-asset treasury will continue to inject volatility into reported results. The value of RAIN token holdings can swing sharply between quarters, meaning headline net income may diverge dramatically from underlying operating performance. Investors should distinguish operating losses from treasury-driven gains or losses.
Third, liquidity and capital structure deserve attention. The company completed a $21 million debt financing and previously reported a strong current ratio (a measure of short-term liquidity comparing current assets to current liabilities) of about 6.43. Combined with the recent reverse split, these items may influence how the company funds future trials and manages its balance sheet.
Finally, cash burn remains a key metric. With no meaningful revenue, R&D spending will dictate how long existing resources last and whether additional financing could eventually dilute shareholders. Watching these elements together, rather than any single headline number, will offer the clearest picture of Enlivex's trajectory. I’m watching this closely as the clinical and treasury elements evolve.
In preparing for earnings seasons like this one, I often turn to Tickeron’s AI Screener to quickly filter for stocks with similar volatility profiles or technical setups. It helps surface relevant patterns without spending hours on manual screening, which is especially handy when balancing biotech catalysts with crypto-related swings. The tool has become a regular part of how I cross-check ideas before digging deeper into individual filings.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.
ENLV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 35 cases where ENLV's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 59 of 69 cases where ENLV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
Following a +9.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where ENLV advanced for three days, in 158 of 198 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ENLV entered a downward trend on November 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.006) is normal, around the industry mean (3.596). P/E Ratio (0.001) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. ENLV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENLV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions
Industry Biotechnology